Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2005009458) USE OF XMP-629 FOR THE TREATMENT OF ACNE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2005/009458 International Application No.: PCT/US2004/023982
Publication Date: 03.02.2005 International Filing Date: 23.07.2004
IPC:
A61K 38/08 (2006.01) ,A61K 38/17 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08
Peptides having 5 to 11 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
Applicants:
LAMBERT, Lewis, H., Jr. [US/US]; US (UsOnly)
VANHOVE, Geertrui F.A. [BE/US]; US (UsOnly)
XOMA TECHNOLOGY LTD. [--/--]; c/o Xoma (US) LLC 2910 Seventh Street Berkeley, CA 94710, US (AllExceptUS)
Inventors:
LAMBERT, Lewis, H., Jr.; US
VANHOVE, Geertrui F.A.; US
Agent:
McNICHOLAS, Janet, M.; McAndrews Held & Malloy, Ltd. 500 West Madison Street, 34th Floor Chicago, IL 60661, US
Priority Data:
60/489,61823.07.2003US
60/554,70519.03.2004US
Title (EN) USE OF XMP-629 FOR THE TREATMENT OF ACNE
(FR) UTILISATION DE XMP-629 POUR LE TRAITEMENT DE L'ACNE
Abstract:
(EN) The present invention provides novel the use of materials including XMP.629 for treating acne, and including methods comprising administering to a subject a composition comprising a therapeutically effective amount of XMP.629 or a pharmaceutically acceptable salt or derivative thereof.
(FR) L'invention concerne l'utilisation de matériaux comprenant du XMP.629 pour le traitement de l'acné, ainsi que des procédés consistant à administrer à un sujet une composition comprenant une dose efficace sur le plan thérapeutique de XMP.629 ou d'un sel ou d'un dérivé associé acceptable sur le pan pharmaceutique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)